Literature DB >> 1331765

Modulation of cardiac cyclic AMP metabolism by adenosine receptor agonists and antagonists.

H Ma1, R D Green.   

Abstract

The mechanism(s) underlying adenosine receptor-mediated modulation of cardiac cAMP levels has been investigated using detergent-permeabilized embryonic chick ventricular myocytes. The beta-adrenergic receptor agonist isoproterenol (ISO) stimulated adenylyl cyclase activity in detergent-permeabilized cells by 5-10-fold, with an EC50 value of 0.3 microM. Three adenosine receptor agonists, (R)-N6-phenylisopropyladenosine, N6-(3-iodo-4-aminobenzyl)adenosine, and 5'-N-ethylcarboxamidoadenosine, inhibited ISO (10 microM)-stimulated adenylyl cyclase activity in a concentration-dependent manner. The maximum inhibition of the ISO-stimulated adenylyl cyclase activity by (R)-N6-phenylisopropyladenosine (10 microM) was 30-40%. This inhibition was antagonized by the adenosine receptor antagonists xanthine amine congener and 8-cyclopentyl-1,3-dipropylxanthine and was abolished by pertussis toxin treatment, suggesting that the inhibition of adenylyl cyclase activity is mediated by A1 adenosine receptors acting via a pertussis toxin-sensitive guanine nucleotide-binding protein (G protein). Because the adenosine receptor agonists had no detectable effect on phosphodiesterase activity, the adenosine receptor-mediated inhibition of adenylyl cyclase activity appears to account for the cAMP-lowering effect of adenosine receptor agonists seen in intact cardiac myocytes. Moreover, two A1 adenosine receptor antagonists, 8-cyclopentyl-1,3-dipropylxanthine and 3-(4-amino)phenethyl-1-propyl-8-cyclopentylxanthine, stimulated basal adenylyl cyclase activity in the absence of an adenosine receptor agonist; this stimulation was abolished by pretreatment of the cells with pertussis toxin. We postulate that "precoupled" A1 adenosine receptor-G protein complexes, present in the cardiac myocytes, exert a tonic inhibitory influence on adenylyl cyclase activity and that some adenosine receptor antagonists remove this tonic inhibition by destabilizing these precoupled receptor-G protein complexes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1331765

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  8 in total

1.  Histamine H3-receptor-mediated [35S]GTP gamma[S] binding: evidence for constitutive activity of the recombinant and native rat and human H3 receptors.

Authors:  A Rouleau; X Ligneau; J Tardivel-Lacombe; S Morisset; F Gbahou; J-C Schwartz; J-M Arrang
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

Review 2.  Review: amino acid domains involved in constitutive activation of G-protein-coupled receptors.

Authors:  P J Pauwels; T Wurch
Journal:  Mol Neurobiol       Date:  1998       Impact factor: 5.590

Review 3.  Compartmentalization of beta-adrenergic signals in cardiomyocytes.

Authors:  Yang K Xiang
Journal:  Circ Res       Date:  2011-07-08       Impact factor: 17.367

Review 4.  Regulation by Ca2+-signaling pathways of adenylyl cyclases.

Authors:  Michelle L Halls; Dermot M F Cooper
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-01-01       Impact factor: 10.005

5.  Evidence for constitutively-active adenosine receptors at mammalian motor nerve endings.

Authors:  Timothy J Searl; Eugene M Silinsky
Journal:  Eur J Pharmacol       Date:  2012-04-20       Impact factor: 4.432

6.  Adenosine receptor-mediated inhibition of cardiac adenylyl cyclase activity may involve multiple receptor subtypes.

Authors:  H Ma; H J Yu; R D Green
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-01       Impact factor: 3.000

7.  Isolation and characterization of an avian A1 adenosine receptor gene and a related cDNA clone.

Authors:  J S Aguilar; F Tan; I Durand; R D Green
Journal:  Biochem J       Date:  1995-05-01       Impact factor: 3.857

8.  Rolofylline, an adenosine A1 receptor antagonist, inhibits osteoclast differentiation as an inverse agonist.

Authors:  Wenjie He; Tuere Wilder; Bruce N Cronstein
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.